A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)
This Phase 3 study investigated two oral treatments, asciminib and nilotinib, for adults aged 18 and over who were recently diagnosed with a specific type of blood cancer called Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). The main goal was to see which drug was better tolerated, meaning caused fewer side effects or less severe ones. Participants were randomly assigned to receive either asciminib or nilotinib. The study had several stages, including an initial treatment phase and an optional phase where patients might stop treatment if their cancer was well controlled, to see if they could remain cancer-free without medication. Key eligibility included a new diagnosis of CML in its chronic phase and good general health.
De un vistazo
Resultados
Resultados de este estudio
Publicado May 2026Se han publicado los resultados de este estudio.
¿De qué trata este estudio?
This research study is looking at two different medicines, asciminib and nilotinib, for people who have recently been diagnosed with a type of blood cancer called Philadelphia chromosome-positive chronic myeloid leukemia (CML). You might hear it called Ph+ CML. This type of CML means there's a specific change in your chromosomes that leads to the cancer.
The main aim of the study is to compare how well people tolerate each of these medicines. "Tolerability" basically means how easy it is for patients to take the drug without experiencing too many bothersome side effects. Doctors want to find treatments that are not only effective but also allow people to maintain a good quality of life. Understanding tolerability helps doctors decide which treatment might be best for different patients.
Participants in the study were randomly assigned to receive either asciminib or nilotinib. This is like flipping a coin to ensure a fair comparison between the two drugs. The study also had longer-term phases. For some patients whose cancer was well-controlled, there was an optional period where they might try to stop their medication altogether to see if their CML remained in remission without continuous treatment. This is a very important part of CML research, as reducing or stopping lifelong medication could significantly improve quality of life for many.
Puntos clave
- Researched two oral drugs (asciminib, nilotinib) for newly diagnosed CML.
- Main goal was to compare how well patients tolerated each drug.
- Included an optional phase to try stopping treatment if cancer was controlled.
- Participants were adults, 18+, with a specific type of CML.
- Study aimed to find treatments that are effective and well-tolerated.
¿Quién puede ser elegible?
To be considered for this study, you would generally need to be an adult, 18 years or older, with a new diagnosis of Philadelphia chromosome-positive chronic myeloid leukemia (CML) in its chronic phase. This means your CML diagnosis should have been made within the last three months, and specific tests would confirm the type and stage of your cancer, showing it's not advanced.
Your general health would also be assessed. You would need to have certain blood counts and organ functions (like liver and kidney) within a healthy range. Researchers also looked for a specific genetic marker (BCR::ABL1 transcript) in your blood, which is characteristic of this type of CML and helps them monitor the disease. Your ability to carry out daily activities would also be checked, ensuring you are well enough to participate.
Essentially, the study was for newly diagnosed adults with a specific, less aggressive form of CML (chronic phase) who were otherwise in reasonably good health. This helps ensure that the study results are clear and that participants can safely take part.
¿Podría este estudio ser adecuado para ti?
Responde estas preguntas rápidas para ver si puedes ser elegible. Esto es solo una guía: el equipo de investigación toma la decisión final.
- ¿Eres un adulto de 18 años o más?
- Have you been diagnosed with Philadelphia chromosome-positive CML within the last 3 months?
- Is your CML in its 'chronic phase' (not advanced)?
- Are your liver, kidney, and blood tests generally within a healthy range?
- Are you generally able to carry out your daily activities without much difficulty?
¿En qué consiste la participación?
If you had joined this study, you would first have given your informed consent, meaning you understood and agreed to take part. After that, you would have been randomly assigned to receive one of the two study medications, either asciminib or nilotinib, both taken by mouth.
The study had three main stages: a treatment phase, where you would regularly take the assigned medication and have check-ups. For those whose cancer was well-controlled, there was an optional 'treatment-free remission' phase, where you might have stopped medication for up to two years. During this time, you'd still have regular monitoring. If your cancer showed signs of returning, or if you and your doctor decided, you would then enter a 'treatment re-initiation' phase and restart medication. The total duration of participation would vary depending on which phases you entered.
Riesgos y beneficios potenciales
Locations (119)
- Rocky Mountain Cancer CentersCódigo postal verificadoDenver, Estados Unidos
- Illinois Cancer CareCódigo postal verificadoPeoria, Estados Unidos
- Regions HospitalCódigo postal verificadoSaint Paul, United States
- Messino Cancer CentersCódigo postal verificadoAsheville, United States
- Oncology Hematology Care IncCódigo postal verificadoCincinnati, Estados Unidos
- Williamette Cancer CenterCódigo postal verificadoEugene, United States
- Texas Oncology P ACódigo postal verificadoBedford, United States
- Texas Oncology PA BedfordCódigo postal verificadoBedford, United States
- Virginia Oncology AssociatesCódigo postal verificadoNorfolk, United States
- Sitio de Investigación de NovartisSolo ciudadCABA, Argentina
- Sitio de Investigación de NovartisCódigo postal verificadoBuenos Aires, Argentina
- Sitio de Investigación de NovartisCódigo postal verificadoBuenos Aires, Argentina
Preguntas comunes
What is Philadelphia chromosome-positive CML?
It's a type of blood cancer where your body makes too many white blood cells. It's linked to a specific change in your chromosomes called the Philadelphia chromosome.
What does "tolerability" mean in this study?
Tolerability refers to how well patients can take a medication. It's about monitoring how many side effects occur, how severe they are, and if people need to stop treatment because of them.
Why were people randomly assigned to treatments?
Random assignment (like flipping a coin) helps ensure that the groups receiving each treatment are as similar as possible, making the comparison between the medicines fair and reliable.
Could I stop treatment if my cancer was under control?
Yes, if your cancer was well-controlled and met specific criteria, you could enter an optional phase to try stopping medication while being closely monitored.
What if I wanted to leave the study early?
You always have the right to withdraw from a clinical study at any point, and doing so would not affect your standard medical care in the future.
Cómo obtener más información
Siempre hable con su médico de cabecera o especialista antes de decidir participar en un estudio.
Discusión
Discusión comunitaria
Impulsado por nuestro foro en community.patient.info. Por favor, sea respetuoso — esto no es un consejo médico.